🇺🇸 FDA
Pipeline program

Bisphosphonate

UX143-CL314

Phase 3 small_molecule active

Quick answer

Bisphosphonate for Osteogenesis Imperfecta is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Osteogenesis Imperfecta
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials